Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross HIV/AIDS Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    Pharmacologic Prevention and Treatment of HIV/AIDS

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when Truvada may be considered medically necessary for HIV pre-exposure prophylaxis or HIV treatment, including prior authorization and documentation requirements, through the pharmacy benefit.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Prevention and Treatment of HIV/AIDS
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionTry generic emtricitabine and tenofovir disoproxil fumarate before Truvada is considered medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 update removed coverage criteria for Apretude, Descovy, Rukobia, Sunlenca, Trogarzo, and Yeztugo.

    The October 1, 2026 annual review removed coverage criteria for Apretude, Descovy, Rukobia, Sunlenca, Trogarzo, and Yeztugo.

    The October 1, 2026 annual review removed references to non-formulary exception reviews.

    The October 1, 2026 annual review removed HCPCS codes J0738, J0739, J0750, J0751, J0752, J0799, J1746, and J1961.

    6Drugs with coverage criteria removed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8
    HCPCS codes removed
    Up to 3 yearsInitial authorization period
    Up to 3 yearsReauthorization period
    Medicare Advantage excludedPlan applicability

    Coverage Criteria

    Truvada medical necessity

    Truvada may be considered medically necessary when all of the following are met.

    Truvada medical necessity: The individual has tried and had an inadequate response or intolerance to generic emtricitabine and tenofovir disoproxil fumarate.

    Continuation therapy

    Reauthorization may be approved when all continuing requirements are met.

    Truvada continuation therapy: Medical necessity criteria remain met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Reauthorization may be approved for up to 3 years.

    Uses of the medications listed in this policy for conditions not outlined in the policy are considered investigational and may be denied. The medications remain subject to the product’s FDA-approved dosage and administration prescribing information.

    This medical policy does not apply to Medicare Advantage. Coverage is also subject to the limits and conditions of the member’s benefit plan; providers and members should consult the member benefit booklet or contact a customer service representative to confirm applicable limitations.

    Initial Therapy Criteria

    Initial Truvada authorization

    Truvada may be considered medically necessary when all of the following are met.

    Initial Truvada therapy: The individual has tried and had an inadequate response or intolerance to generic emtricitabine and tenofovir disoproxil fumarate.

    Initial authorization may be approved for up to 3 years.

    Continuation Therapy Criteria

    Truvada continuation therapy

    Truvada reauthorization may be approved when all of the following are met.

    Continuing Truvada therapy: Medical necessity criteria continue to be met and chart notes demonstrate a positive clinical response to therapy.

    Approval may be granted for up to 3 years.

    Required Generic Trial

    StepMedication requirementRequired outcome
    1Try generic emtricitabine and tenofovir disoproxil fumarate before Truvada.Inadequate response or intolerance to the generic combination.

    Benefit Administration

    Billing Rule

    Pharmacy Benefit

    Truvada (emtricitabine and tenofovir disoproxil fumarate) is managed through the pharmacy benefit.

    Coding Information

    Historical HCPCS coding updatesHCPCS
    J3490Historical HCPCS code added for Trogarzo and later Sunlenca coding updates
    J3590Historical HCPCS code added for Trogarzo
    J1746Historical HCPCS code for Trogarzo, effective 1/1/19
    J0739Historical HCPCS code added for Apretude
    J1961Historical HCPCS code added in a 2023 coding update
    Removed HCPCS codesHCPCS
    J0738HCPCS code removed from the policy
    J0739HCPCS code removed from the policy
    J0750HCPCS code removed from the policy
    J0751HCPCS code removed from the policy
    J0752HCPCS code removed from the policy
    J0799HCPCS code removed from the policy
    J1746HCPCS code removed from the policy
    J1961HCPCS code removed from the policy
    AIDS CD4+ T-cell threshold
    ThresholdBelow 200 cells/mm³
    Clinical significanceA CD4+ T-cell count below this threshold is a defining criterion for AIDS.
    Alternative AIDS criterionThe presence of an AIDS-defining illness also meets the definition of AIDS.

    Provider Requirements and Actions

    Prior Authorization

    Meet Truvada authorization criteria

    Submit Truvada requests only when the individual has tried and had an inadequate response or intolerance to generic emtricitabine and tenofovir disoproxil fumarate. Initial authorization may be approved for up to 3 years.

    Step Therapy

    Try the generic combination first

    Document that the individual tried generic emtricitabine and tenofovir disoproxil fumarate before requesting Truvada. The trial must have resulted in an inadequate response or intolerance.

    Documentation Required

    Submit clinical records and medication history

    Clinical Background

    HIV is a chronic, progressive infection that primarily targets and depletes CD4+ T-cell lymphocytes, which are essential to immune function. Progression can lead to AIDS, opportunistic infections, and malignancies. Antiretroviral therapy suppresses viral replication, supports immune recovery, reduces morbidity and mortality, and can prevent sexual transmission when viral suppression is achieved. Although HIV is generally a manageable chronic condition, chronic immune activation and non-AIDS comorbidities remain concerns.

    Key Definitions

    Pre-exposure prophylaxis (PrEP)
    TermPre-exposure prophylaxis (PrEP)
    DefinitionThe use of FDA-approved medications by individuals without HIV.
    PurposeTo significantly reduce the chance of acquiring HIV.
    AIDS
    DefinitionAIDS is defined by a CD4+ T-cell count below 200 cells/mm³ or the presence of an AIDS-defining illness.
    CD4+ T-cell criterionBelow 200 cells/mm³.
    Illness criterionPresence of an AIDS-defining illness.
    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Prevention and Treatment of HIV/AIDS
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionTry generic emtricitabine and tenofovir disoproxil fumarate before Truvada is considered medically necessary.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaRequired Generic TrialBenefit AdministrationCoding InformationProvider Requirements and ActionsClinical BackgroundKey Definitions

    Submit medical records documenting that medical necessity criteria are met. Include office visit notes with the diagnosis, relevant history, physical evaluation, and medication history.

    Documentation Required

    Document ongoing clinical response

    For reauthorization, submit chart notes demonstrating that the individual continues to show a positive clinical response to therapy. Reauthorization may be approved for up to 3 years when medical necessity criteria continue to be met.

    Documentation Required

    Verify member benefits

    Verify coverage before treatment by consulting the member benefit booklet or contacting a customer service or member service representative to determine applicable benefit limitations and coverage for the specific drug or treatment.

    Denial Risk

    Unlisted uses may be denied

    Uses of medications listed in this policy for conditions not outlined in the policy are considered investigational and may be denied. Ensure the requested use matches the policy conditions and the product’s FDA dosage and administration prescribing information.

    Denial Risk

    Confirm benefit and plan applicability

    Coverage may be limited or unavailable when the member’s benefit plan does not include the requested drug, service, or supply. This policy does not apply to Medicare Advantage; consult the member benefit booklet or a customer service representative for plan-specific limitations.

    U=U (Undetectable Equals Untransmittable)
    MeaningUndetectable equals untransmittable.
    DefinitionEffective antiretroviral therapy suppresses HIV to undetectable levels.
    Prevention effectUndetectable HIV levels prevent sexual transmission of HIV.